Pharmaceuticals & Biotech Italian Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Italian Investing Ideas
AN
Consensus Narrative from 10 Analysts
Rare Disease Products Expected To Strengthen Future Prospects
Key Takeaways Rare Disease segment growth and Isturisa label expansion are expected to significantly boost future revenue and earnings. Strong financial health and strategic acquisitions indicate potential for continued revenue growth and enhanced shareholder value.
View narrative€58.97
FV
14.0% undervalued intrinsic discount7.85%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
4 days ago author updated this narrative